A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates

Antiviral Res. 1991 Oct;16(3):257-66. doi: 10.1016/0166-3542(91)90005-c.

Abstract

R82913, (+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)- imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione (a TIBO derivative), inhibited the replication of thirteen different strains of HIV-1 in CEM cells with a median IC50 of 0.15 microM. The concentration of compound that killed 50% of the cells was much higher (46 microM), indicating that R82913 has a high selectivity index. R82913 was 20-fold more potent than AZT-TP in the inhibition of HIV-1 reverse transcriptase in an assay using a naturally occurring template (ribosomal RNA) that more accurately resembles native viral RNA than a synthetic homopolymer. With this template, R82913 inhibited HIV-1 reverse transcriptase with an ID50 (0.01 microM) that is equal to, or lower than, the IC50 for this compound in all of our cell culture assays (0.01-0.65 microM). R82913 has no effect on the replication of HIV-2 in CEM cells and does not inhibit the reverse transcriptase from this virus.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Base Sequence
  • Benzodiazepines / pharmacology*
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-2 / drug effects*
  • HIV-2 / enzymology
  • Imidazoles / pharmacology*
  • Molecular Sequence Data
  • Retroviridae Proteins / antagonists & inhibitors*
  • Reverse Transcriptase Inhibitors*
  • Templates, Genetic
  • Zidovudine / pharmacology

Substances

  • Imidazoles
  • Retroviridae Proteins
  • Reverse Transcriptase Inhibitors
  • Benzodiazepines
  • Zidovudine
  • R-82913